Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 5, 1999, Pages 463-467

  Hanson, I Celine ^a,i   Antonelli, Tracy A ^b   Sperling, Rhoda S ^c   Oleske, James M ^d   Cooper, Ellen ^e   Culnane, Mary ^f   Fowler, Mary Glenn ^f   Kalish, Leslie A ^b   Lee, Sophia S ^g   McSherry, George ^d   Mofenson, Lynne ^h   Shapiro, David E ^g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e BOSTON MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Carcinogenesis; Perinatal HIV transmission; Perinatal HIV transmission prophylaxis; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERINATAL PERIOD; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; VERTICAL TRANSMISSION; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033560997     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199904150-00008     Document Type: Article

References (14)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. U.S. Centers for Disease Control and Prevention. Public health service task force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43:1-21.
3. U.S. Centers for Disease Control and Prevention. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep 1995;44:1-14.
4. Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996;174:1207-11.
5. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996;275:1483-8.
6. Mayaux J-M, Teglas J-P, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr 1997; 131:857-62.
7. Simonds RJ, Steketee R, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS 1998;12:301-8.
8. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus from mother to infant. N Engl J Med 1996; 336:1621-9.
9. Ayers KM, Clive D, Tucker WE Jr, Hajian G, De Miranda P. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundm Appl Toxicol 1996;26:148-58.
10. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997;89:1602-8.
11. Ayers K M. Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in Cd-1 mice with zidovudine. Fundm Appl Toxicol 1997;38:195-8.
12. U.S. Centers for Disease Control and Prevention. Public health service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47:1-30.
13. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Cancer 1995;75:2186-95.
14. Pearson ES, Hartley HO. Biometrika tables for statisticians, 3rd ed. London: Biometrika Trust, 1976.